Can-Fite BioPharma (CANF) said Monday it expects to generate $685 million in projected future revenues from its collaborations.
The company said it currently has seven partnerships, one of the biggest with EwoPharma, with a potential revenue of about $113 million. These deals include milestone payments, royalties, manufacturing fees, and sales-based earnings.
The company said it also expects "substantial" revenue over the next decade from its lead drug candidates, Piclidenoson and Namodenoson. These drugs are in development for psoriasis, advanced liver cancer, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis, or MASH.
Can-Fite BioPharma shares were up 1.58% in recent trading Monday before the trading was halted pending material news.
Price: 1.60, Change: +0.02, Percent Change: +1.59
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.